Hyperglycemia is most commonly seen with PI3K-α inhibition (selective and pan-inhibitors), due to therapy induced disruptions in insulin signaling and glucose hemostasis leading to clinically evident metabolic changes (243). This evidence concerns the gene INS and Hyperglycemia.